New hope for lung cancer patients who stopped responding to targeted therapy

NCT ID NCT05870319

Ongoing Disease control Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests a new drug called SKB264 against standard chemotherapy in 376 adults with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to targeted therapy. The goal is to see if SKB264 can slow cancer growth better than chemo. Participants receive either SKB264 alone or a chemo combination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SKB264 (a drug given by IV infusion)
What this could lead to: If it works, this could offer a new treatment option for people with a common type of lung cancer that has stopped responding to current targeted therapies.
What could go wrong: This is a late-stage trial, but the drug is still experimental. It may not prove better than standard chemo, and side effects are possible. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.